The present invention relates to whey protein micelles for use in the treatment and/or prevention of a disorder linked to an increase in plasma postprandial insulin and/or plasma postprandial glucagon concentration in a subject. The invention relates also to a non-therapeutic use of whey protein micelles to decrease plasma postprandial insulin and/or glucagon concentration in healthy subjects.

Methods are described for treating a whey protein mixture to increase a relative concentration of -lactalbumin protein in the mixture. The methods may include the step of adjusting a temperature of the whey protein mixture to about 10 C. or less, and adjusting the pH of the mixture to greater than 7. The may further include adding a protease enzyme to the whey protein mixture that selectively hydrolyzes -lactoglobulin protein in the mixture. The activity of the protease enzyme in the hydrolyzed whey protein mixture may be terminated before a substantial portion of the -lactalbumin protein has been hydrolyzed by the enzyme. In some instances, the whey protein mixture may also include glycomacropeptides that are selectively hydrolyzed with the -lactoglobulin protein. The -lactoglobulin and glycomacropeptide hydrolysates may be separated to produce an enhanced -lactalbumin protein composition for infant formula, among other products.

Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of Men A saccharide: MenC saccharide is >1.

Novel methods for producing whey protein concentrates with favorable properties are provided. The methods include using chitosan selective precipitation whey pre-treatment, and microfiltration using polymeric membranes. The products obtained using these methods include WPC80 with low fat content, high clarity, low browning potential during storage, and having low levels of volatiles. Compositions and foaming agents obtained using the methods of the present invention are also provided.

An embodiment of the present invention relates to protein granules containing a whey protein as a main component, the protein granules having an average particle diameter of 207 m to 570 m, a homogeneity U of 0.58 or less, a content ratio (volume ratio) of coarse powder having a particle diameter of 500 m or more of 22% or less, and a content ratio (volume ratio) of fine powder having a particle diameter of 150 m or less of 31% or less.

The present invention relates to a method for the preparation of a concentrate of serum proteins with reduced lactose content from a sample of lactoserum, wherein said concentrate is characterized in that it comprises a concentration of 0.5 grams of lactose per kilogram of protein, the concentrate obtainable from said process and food products containing said concentrate.

A process of preparing a shelf-stable liquid enteral nutritional composition, said process comprising the steps of providing an oil-in-water emulsion, sterilizing the emulsion by direct steam injection (DSI) to obtain a sterilized emulsion with a F.sub.0 value of at least 3 and subjecting the sterilized emulsion to high pressure homogenization.

The present invention pertains to a new type of CMP-containing, high protein denatured whey protein compositions and to a method of producing them. The invention furthermore pertains to products containing the high protein denatured whey protein compositions, particularly high protein, acidified dairy products, and additional uses of the denatured whey protein compositions.

The present disclosure includes denatured whey protein compositions. The compositions include at least 60 wt. % protein on a dry weight basis, less than 8 wt. % native glycomacropeptide (GMP), greater than 2 wt. % enzymatically hydrolyzed GMP relative to the total weight of the protein, a proteolysis index of at least 8 wt. %, and greater than 50 wt. % denatured whey proteins relative to the total weight of the protein.

The present disclosure relates to a denatured whey protein composition. The denatured whey protein composition comprises submicrometre particles having a volume weighted mean diameter D(4,3) of not more than 1 m and a substantially monomodal distribution wherein at least 95% by volume of the particles are not more than 2 m. The present disclosure also relates to high protein beverages, food products, and nutritional compositions comprising such denatured whey protein compositions and methods for manufacturing such denatured whey protein compositions.